About Immusoft
Immusoft is a company based in Seattle (United States) founded in 2009 by Matthew Scholz. Immusoft has raised $44.13 million across 15 funding rounds from investors including ARE, State of California and NIH. Immusoft has completed 1 acquisition, including Discovery Genomics. Immusoft offers products and services including Immune System Programming (ISP™) and B Cell Biofactory Technology. Immusoft operates in a competitive market with competitors including Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
- Headquarter Seattle, United States
- Founders Matthew Scholz
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Immusoft Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$44.13 M (USD)
in 15 rounds
-
Latest Funding Round
$4.58 M (USD), Series B
May 28, 2024
-
Investors
ARE
& 17 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Immusoft
Immusoft offers a comprehensive portfolio of products and services, including Immune System Programming (ISP™) and B Cell Biofactory Technology.
Engineers B cells to produce therapeutic proteins for genetic diseases.
Programs cells for long-term protein secretion in patients.
People of Immusoft
Unlock access to complete
Unlock access to complete
Funding Insights of Immusoft
Immusoft has successfully raised a total of $44.13M across 15 strategic funding rounds. The most recent funding activity was a Series B round of $4.58 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Immusoft
Immusoft has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, State of California and NIH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Biovision Ventures is focused on investing in life sciences and healthcare innovations.
|
Locked | Locked | Locked | |
|
RV Invest is engaged in funding biotech innovations.
|
Locked | Locked | Locked |
Investor details for Immusoft
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Immusoft
Immusoft has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Discovery Genomics.
Investment portfolio details for Immusoft
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Gene therapies for blood diseases
|
Locked | Locked | 2000 | Locked |
Complete acquisition details for Immusoft
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Immusoft
Detailed financials for Immusoft
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Immusoft Comparisons
Peer comparison for Immusoft
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Immusoft
Immusoft operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of precision therapeutics for dry AMD and rare genetic diseases
|
|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| Locked | Locked | Locked |
B cell therapies are developed for oncology and rare diseases.
|
Detailed competitors of Immusoft
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immusoft
Complete news archive for Immusoft
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immusoft
Immusoft was founded in 2009 and raised its 1st funding round 3 years after it was founded.
Immusoft is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Immusoft is a funded company, having raised a total of $44.13M across 15 funding rounds to date.
Immusoft was founded in 2009 in Seattle, United States, within the biotechnology sector focused on cell therapies. Patient B cells are collected, engineered to generate personalized proteins, expanded in number, and reinfused to act as ongoing production sites. This method supports sustained in vivo protein expression for medical applications, with operations centered on developing these programmable cellular systems.
Immusoft's top competitors include Alnylam, BioMarin Pharmaceutical and Be Bio.
Immusoft offers Immune System Programming (ISP™) and B Cell Biofactory Technology.
Immusoft has made 1 acquisition, including Discovery Genomics.
Immusoft has 18 investors. Key investors include ARE, State of California, NIH, HHS, and NYBC Ventures.